The Dobbs v Jackson Women’s Health Organization decision has significantly influenced ob-gyn residency applications, particularly in states with complete abortion bans, leading to notable shifts in applicant preferences and program dynamics.
Match Day caps a momentous year of major changes in our chosen field because of the Dobbs v Jackson Women’s Health Organization decision. Of note, it has significantly impacted the number of obstetrics and gynecology (ob-gyn) applicants and where they apply geographically.
Post Dobbs, 14 states now have full bans on abortion.1 The Accreditation Commission on Colleges of Medicine has evaluated its impact on residency applications to programs in these 14 states and found the following2:
States with complete bans had fewer residency applicants from US MDs across all specialties. In a survey of 494 medical students, 77% responded that changes in abortion access would likely or very likely influence their decision in consideration of residency programs.3 The students highlighted the importance of access for their patients, themselves, and their family.
In 2023, ob-gyn programs had the second largest drop in applicants across all states, with a 5.5% reduction (emergency medicine saw the largest drop in applicants, –21.4%). The decrease in applicants was highest in states with complete abortion bans (–10.5%) and lowest in those without restrictions. By comparison, in 2024, the number of applicants in ob-gyn was relatively stable (Table).4
Despite these trends, all residency positions in ob-gyn were filled, and if our program is an example, we have fantastic residents and trainees with bright futures. This Match Day brought home to me the incredible significance of the day—the next years of life for our graduates are decided with joy and some sorrow. I am humbled by the opportunities and challenges our trainees face, as the practice of medicine now has additional challenges of navigating legal implications on practice. It is vital we support them and encourage them to practice in all parts of the country to ensure access to care for women. For many women, their ob-gyn is their only medical home for years of their life.
Note the decline of 5.5% in 2023 after the Dobbs decision.
References
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen